全文获取类型
收费全文 | 57371篇 |
免费 | 5478篇 |
国内免费 | 94篇 |
专业分类
耳鼻咽喉 | 586篇 |
儿科学 | 1817篇 |
妇产科学 | 1452篇 |
基础医学 | 8140篇 |
口腔科学 | 1678篇 |
临床医学 | 7020篇 |
内科学 | 10975篇 |
皮肤病学 | 685篇 |
神经病学 | 5508篇 |
特种医学 | 1555篇 |
外国民族医学 | 2篇 |
外科学 | 6521篇 |
综合类 | 1175篇 |
一般理论 | 74篇 |
预防医学 | 6723篇 |
眼科学 | 1390篇 |
药学 | 4236篇 |
1篇 | |
中国医学 | 55篇 |
肿瘤学 | 3350篇 |
出版年
2023年 | 332篇 |
2022年 | 460篇 |
2021年 | 988篇 |
2020年 | 673篇 |
2019年 | 1083篇 |
2018年 | 1182篇 |
2017年 | 901篇 |
2016年 | 939篇 |
2015年 | 1106篇 |
2014年 | 1572篇 |
2013年 | 2294篇 |
2012年 | 3243篇 |
2011年 | 3396篇 |
2010年 | 1809篇 |
2009年 | 1758篇 |
2008年 | 2881篇 |
2007年 | 3117篇 |
2006年 | 2972篇 |
2005年 | 2950篇 |
2004年 | 2774篇 |
2003年 | 2595篇 |
2002年 | 2489篇 |
2001年 | 1258篇 |
2000年 | 1271篇 |
1999年 | 1216篇 |
1998年 | 603篇 |
1997年 | 499篇 |
1996年 | 498篇 |
1995年 | 462篇 |
1994年 | 431篇 |
1993年 | 452篇 |
1992年 | 935篇 |
1991年 | 910篇 |
1990年 | 924篇 |
1989年 | 832篇 |
1988年 | 781篇 |
1987年 | 780篇 |
1986年 | 730篇 |
1985年 | 751篇 |
1984年 | 576篇 |
1983年 | 551篇 |
1982年 | 374篇 |
1981年 | 375篇 |
1980年 | 353篇 |
1979年 | 512篇 |
1978年 | 416篇 |
1977年 | 339篇 |
1974年 | 412篇 |
1973年 | 405篇 |
1971年 | 332篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Timothy J. Cordingley Mark A.G. Wilson Kathryn M. Weston 《Health & social care in the community》2022,30(1):353-359
Vaccination is a vital health care initiative to prevent individual and population infection. To increase vaccination rates the federal government implemented the ‘No Jab, No Pay’ policy, where eligibility for several government benefits required children to be fully vaccinated by removing ‘conscientious objections’ and expanding the age range of children whose families receive benefits. This study assesses the impact of this policy at a local area within a single medical practice community in NSW, Australia. A retrospective clinical audit was performed between 2012 and 2017 on a single general practice's vaccination records for children ≤19 years. Catch-up vaccinations were assessed based on age at vaccination. Incidence of catch-up vaccinations was assessed for each of four years before and two years after the implementation of the ‘No Jab, No Pay’ policy in January 2016, along with the age of children and vaccination(s) given. Catch-up vaccinations were assessed temporally either side of implementation of ‘No Jab, No Pay’. Comparing the average annual vaccination catch-up incidence rate of 6.2% pre-implementation (2012–2015), there was an increase to 9.2% in 2016 (p < .001) and 7.8% in 2017 (p = .027). Secondary outcome measurement of catch-up vaccination incidence rates before (2012–2015) and after (2016–2017) ‘No Jab, No Pay’ implementation showed statistically significant increases for children aged 8–11 years (3.2%–5.6%, p = .038), 12–15 years (7.5%–14.7%, p < .001) and 16–19 years (3.3%–10.2%, p < .001) along with a statistically significant reduction in children aged 1–3 years (11.4%–6.2%, p = .015). Also, catch-up rates for DTPa significantly increased after program implementation. This study demonstrates that the Australian federal government vaccination policy ‘No Jab, No Pay’ was coincident with an increase in catch-up vaccinations within a rural NSW community served by one medical practice, especially for older children. 相似文献
2.
James A. Akingbasote Alison J. Foster Ian Wilson Sunil Sarda Huw B. Jones J. Gerry Kenna 《Archives of toxicology》2016,90(4):853-862
Hepatic NADPH-cytochrome P450 oxidoreductase null (HRN?) mice exhibit normal hepatic and extrahepatic biotransformation enzyme activities when compared to wild-type (WT) mice, but express no functional hepatic cytochrome P450 activities. When incubated in vitro with [14C]-diclofenac, liver microsomes from WT mice exhibited extensive biotransformation to oxidative and glucuronide metabolites and covalent binding to proteins was also observed. In contrast, whereas glucuronide conjugates and a quinone-imine metabolite were formed when [14C]-diclofenac was incubated with HRN? mouse liver, only small quantities of P450-derived oxidative metabolites were produced in these samples and covalent binding to proteins was not observed. Livers from vehicle-treated HRN? mice exhibited enhanced lipid accumulation, bile duct proliferation, hepatocellular degeneration and necrosis and inflammatory cell infiltration, which were not present in livers from WT mice. Elevated liver-derived alanine aminotransferase, glutamate dehydrogenase and alkaline phosphatase activities were also observed in plasma from HRN? mice. When treated orally with diclofenac for 7 days, at 30 mg/kg/day, the severities of the abnormal liver histopathology and plasma liver enzyme findings in HRN? mice were reduced markedly. Oral diclofenac administration did not alter the liver histopathology or elevate plasma enzyme activities of WT mice. These findings indicate that HRN? mice are valuable for exploration of the role played by hepatic P450s in drug biotransformation, but poorly suited to investigations of drug-induced liver toxicity. Nevertheless, studies in HRN? mice could provide novel insights into the role played by inflammation in liver injury and may aid the evaluation of new strategies for its treatment. 相似文献
3.
Rocha Déborah Ribeiro Nery Jaqueline Freire Furini Leonardo Negri Constantino Carlos José Leopoldo Eller Lizziane Kretli Winkelströter Nai Gisele Alborghetti Nakagaki Wilson Romero 《Lasers in medical science》2020,35(8):1703-1709
Lasers in Medical Science - Studies reported the harmful effects of 2,4-D on body tissues, provoking changes in the anatomy and physiology of the kidneys, liver, and testicles. Thus, the objective... 相似文献
4.
5.
6.
7.
8.
Leyi Wang Saraswathi Lanka Debbie Cassout Nohra E. Mateus‐Pinilla Ganwu Li William C. Wilson Dongwan Yoo Paul Shelton Richard L. Fredrickson 《Transboundary and Emerging Diseases》2019,66(5):1809-1820
First described in 1955 in New Jersey, epizootic haemorrhagic disease (EHD) causes a severe clinical disease in wild and domestic ruminants worldwide. Epizootic haemorrhagic disease outbreaks occur in deer populations each year from summer to late autumn. The etiological agent is EHD virus (EHDV) which is a double‐stranded segmented icosahedral RNA virus. EHD virus utilizes point mutations and reassortment strategies to maintain viral fitness during infection. In 2018, EHDV serotype 2 was predominantly detected in deer in Illinois. Whole genome sequencing was conducted for two 2018 EHDV2 isolates (IL41747 and IL42218) and the sequence analyses indicated that IL42218 was a reassortant between different serotypes whereas IL41747 was a genetically stable strain. Our data suggest that multiple strains contribute to outbreaks each year. 相似文献
9.
10.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献